BHCHealthcare · Drug Manufacturers - Specialty & GenericThe 7 Wall Street analysts covering Bausch Health Cos., Inc. hold a median 12-month price target of $7 — +18.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 99 of 100 as at 9 Oct 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Bausch Health Cos., Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (99): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Momentum (51): The shares have been drifting down relative to others.
Size (34): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on BHC, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +18.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 27 Apr 2026 | RBC Capital | Maintains | Sector Perform | $10 → $9.00 |
| 25 Feb 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 Jan 2026 | Truist Securities | Maintains | Hold | — |
| 9 Dec 2025 | Barclays | Initiates | Equal-Weight | — |
| 2 May 2025 | RBC Capital | Maintains | Sector Perform | — |
| 6 Feb 2025 | Jefferies | Downgrade | Hold | — |
| 30 Jan 2025 | RBC Capital | Maintains | Sector Perform | — |
| 1 Nov 2024 | RBC Capital | Maintains | Sector Perform | — |
| 2 Aug 2024 | Piper Sandler | Downgrade | Underweight | — |
| 2 Aug 2024 | RBC Capital | Maintains | Sector Perform | — |
| 25 July 2024 | Truist Securities | Maintains | Hold | — |
| 10 July 2024 | Raymond James | Initiates | Market Perform | — |
| 23 Apr 2024 | RBC Capital | Maintains | Sector Perform | — |
| 12 Apr 2024 | RBC Capital | Reiterates | Sector Perform | — |
| 5 Apr 2024 | RBC Capital | Maintains | Sector Perform | — |
| 23 Feb 2024 | RBC Capital | Maintains | Sector Perform | — |
| 20 Sept 2023 | Jefferies | Upgrade | Buy | — |
| 16 June 2023 | TD Cowen | Downgrade | Market Perform | — |
| 22 May 2023 | Jefferies | Maintains | Buy | — |
| 5 May 2023 | RBC Capital | Maintains | Sector Perform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
BHC appears in the Radar on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 12 Oct 2026, Bausch Health Cos., Inc. returned −2.0% against +20.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 49% of US stocks
Cheaper than 90% of US stocks
Cheaper than 96% of US stocks
Cheaper than 52% of US stocks
Higher than 59% of US stocks
Higher than 80% of US stocks
Higher than 85% of US stocks
Higher than 85% of US stocks
Higher than 20% of US stocks
Higher than 91% of US stocks
Higher than 83% of US stocks
Higher than 99% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Bausch Health Cos., Inc. has a market value of $2.4B and an enterprise value of $22.3B.
Revenue in the twelve months to 30 June 2026: $10.9B. The latest quarter grew 12.7% year on year.
Net income over the same four quarters: −$1.1B, a −10.1% net margin.
Diluted earnings per share, trailing twelve months: $−2.96.
Free cash flow in the twelve months to 30 June 2026: $1.4B.
Trailing P/E: 13.3×; forward P/E: 1.5× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 62.06%, paying out 0% of earnings.
Bausch Health Cos., Inc. employs 20,300 people — $535K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Bausch Health Cos., Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Bausch Health is scheduled to report Q3 2026 results on Oct. 28, with sales expected to reach $2.75 billion. The preview highlights segment drivers and a mixed history of earnings surprises.
Why it matters — The report outlines expectations and context for BHC’s upcoming quarterly results.
Bausch Health and Salix announced that a multicenter pilot study found improved adherence to evidence-based monitoring and treatment practices after implementing a standardized cirrhosis clinical pathway in community gastroenterology settings. Findings are slated for presentation as a poster at the 2026 ACG Annual Scientific Meeting.
Why it matters — The results highlight Salix’s work in gastroenterology and the use of a standardized pathway to support cirrhosis management.
Bausch + Lomb and Bausch Health announced that Bausch Health CEO Thomas J. Appio will become interim CEO of Bausch + Lomb, effective immediately. Appio will continue to lead Bausch Health while taking on the additional role.
Why it matters — BHC shareholders may note that the parent company’s CEO is now also leading its subsidiary on an interim basis.
Bausch Health will release its third-quarter 2026 financial results after market close on October 28, 2026. The company will host a live conference call and webcast at 5:00 p.m.
Why it matters — BHC watchers can follow the scheduled results release and management's accompanying call for quarterly updates.
A Zacks Investment Research report highlights BHC among a group of low-beta healthcare stocks, alongside ABT, CORT and PGEN, positioned as defensive exposure amid fears of another rate hike and ongoing market volatility.
Why it matters — The mention of BHC as a low-beta healthcare name in a rate-hike environment signals that analysts view the stock as a relatively defensive option for healthcare investors.
The 7 Wall Street analysts covering Bausch Health Cos., Inc. have a median 12-month price target of $7, with estimates ranging from $6.5 to $9. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Bausch Health Cos., Inc., 0 rate it a Buy, 7 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Bausch Health Cos., Inc. 99 out of 100 across roughly 4,600 US stocks as at 9 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 9 Oct 2026, Bausch Health Cos., Inc. ranks 99 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Value (99 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +18.0% from the last close, and Ticker Nerd's factor model ranks Bausch Health Cos., Inc. 99 out of 100 as at 9 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Bausch Health Cos., Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BHC are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $6.5 to $9 over the next 12 months.
Bausch Health Cos., Inc. returned -2.0% over the 12 months to 12 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Bausch Health Companies Inc. is a diversified specialty pharmaceutical and medical device company focused on developing, manufacturing, and marketing healthcare products across multiple therapeutic areas.
The most recent item we track (Zacks Investment Research, 26 Oct 2026): "BHC Q3 Earnings Preview: Here's What You Should Know". Bausch Health is scheduled to report Q3 2026 results on Oct. 28, with sales expected to reach $2.75 billion. The preview highlights segment drivers and a mixed history of earnings surprises.
Bausch Health Companies Inc. is a diversified specialty pharmaceutical and medical device company focused on developing, manufacturing, and marketing healthcare products across multiple therapeutic areas. Bausch Health serves the gastroenterology, hepatology, neurology, dermatology, dentistry, aesthetics, international pharmaceuticals, and eye health markets, with a portfolio that includes branded, generic, and over-the-counter medicines as well as medical devices. Its operations are organized around products and services used in treating conditions such as digestive disorders, skin diseases, neurological conditions, and vision-related care. The company also supports hospital and clinic needs through its medical device and ophthalmic businesses. Headquartered in Laval, Quebec, Bausch Health plays a significant role in the global healthcare market by supplying therapies and devices used by patients, physicians, and healthcare providers across the United States and international markets.
CEO Mr. Thomas J. Appio · 20,300 employees · Canada · https://www.bauschhealth.com
